Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Offers New SeqCalling Gene Expression Product

Premium

NEW HAVEN, Conn.--CuraGen recently announced the launch of a product line based on SeqCalling, a proprietary process for rapidly generating sequence information by focusing on expressed genes and regions of the genes that code for proteins. SeqCalling locates rarely expressed genes without the problem of nonproductive resequencing of abundant genes, and without sequencing noncoding DNA, the company claimed.

Human and rodent SeqCalling databases are available with broad coverage of the expressed genomes. Current SeqCalling databases provide detailed information on specific species and tissues of interest. For example, the rat liver database contains more than 75 percent of all the genes expressed in that organ and is helpful in understanding drug toxicity.

The product line will accelerate the discovery of protein therapeutics, targets for small-molecule drugs, and gene-based single-nucleotide polymorphisms, CuraGen claimed.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.